Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.
cisatracurium besylate 10 mg/mL Injection — NDC 72785-0009-6 (Billing 72785-0009-06)
by Zydus Lifesciences Limited · 10 VIAL in 1 CARTON / 20 mL in 1 VIAL
This is a package of cisatracurium besylate 10 mg/mL Injection from Zydus Lifesciences Limited, marketed since Feb 2020 and currently FDA-listed. It is this product's only package size.
NDC 72785-0009-06
🏷️ FDA NDC (as labeled)
72785-0009-6
billing pads the package segment with a zero
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
NDC database record
One package, one record: these facts belong to NDC 72785-0009-6 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 72785 labeler · 0009 product · 6 package
- Package marketed since
- Feb 12, 2020
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 7278500096 5
- FDA record last changed
- Jul 24, 2026
⚠️
Other active recalls for Cisatracurium Besylate (different manufacturers) — 3 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class III · Nov 26, 2025 — Subpotent product:out of specification assay results observed during long term stability testing. (SOMERSET THERAPEUTICS LLC) · FDA recall D-0238-2026
Class III · Nov 26, 2025 — Subpotent product:out of specification assay results observed during long term stability testing. (SOMERSET THERAPEUTICS LLC) · FDA recall D-0237-2026
Class III · Nov 26, 2025 — Subpotent product:out of specification assay results observed during long term stability testing. (SOMERSET THERAPEUTICS LLC) · FDA recall D-0236-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
FDA NDC (as labeled)
72785-0009-6
Product NDC
72785-0009
11-digit billing NDC
72785000906
UNII
80YS8O1MBS
Application #
ANDA212171
SPL Set ID
e145a40e-b046-4064-b35e-0da40ff3703e
Established class (EPC)
Nondepolarizing Neuromuscular Blocker
Physiologic effect
Neuromuscular Nondepolarizing Blockade
DEA schedule
Non-controlled
Marketing category
ANDA
Marketing status
On market
FDA listing status
Listed (active directory)
Marketing start
2020-02-12
Route
INTRAVENOUS
Dosage form
INJECTION
Substance
CISATRACURIUM BESYLATE
TE code (Orange Book)
AP · RLD · RS
Quick answers
- RxCUI (RxNorm): 199212
Why two NDCs?
The FDA registers this code as 72785-0009-6 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 72785-0009-06. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 8, 2026
RxNorm drug class
This medicine belongs to the Nondepolarizing Neuromuscular Blocker class.
Pharmacologic class
Nondepolarizing Neuromuscular Blocker
Drug family (ATC)
Other quaternary ammonium compounds
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
📗 Our plain-language guide HelloPharmacist
- It relaxes your muscles during anesthesia so a breathing tube can be placed and surgery can be done safely. It is also used in adults on a breathing machine in the ICU. You will al...
- It is given only through an IV by trained clinicians, either as an injection or a continuous drip. They adjust the amount to how you respond and check your muscles with a nerve sti...
- Side effects are uncommon. They can include a slow heart rate, low blood pressure, flushing, airway tightening or a rash. Your care team watches for these and can treat them quickl...
- Yes. Mention any allergic reactions to anesthesia medicines, muscle diseases like myasthenia gravis, and kidney or liver problems. Also tell them about medicines such as phenytoin,...
Patient education
Supplement & herbal interactions
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
- MedlinePlus (NLM) · refreshed Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
💬 Questions about cisatracurium besylate?
Ask a pharmacist →
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 8, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 72785-0009-06 You're viewing this Main listing | 10 VIAL in 1 CARTON / 20 mL in 1 VIAL | 2020-02-12 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Cisatracurium Besylate 10 mg/mL 00143-9160-10 | Hikma | 10 vials | — | AP | FDA listed | — |
| Cisatracurium Besylate 10 mg/mL 00409-1103-01 | Hospira, | 10 vials | — | AP | FDA listed | — |
| cisatracurium besylate 10 mg/mL 00781-3153-95 | Sandoz | 1 vial | — | AP | FDA listed | — |
| Cisatracurium Besylate 10 mg/mL 31722-0312-10 | Camber | 10 vials | — | AP | FDA listed | — |
| Cisatracurium 10 mg/mL 63323-0418-20 | Fresenius | 10 vials | — | AP | FDA listed | — |
| Cisatracurium besylate 10 mg/mL 65145-0137-01 | Caplin | 1 vial | — | AP | FDA listed | — |
| Cisatracurium besylate 10 mg/mL 68083-0487-01 | Gland | 1 vial | — | AP | FDA listed | — |
| Cisatracurium Besylate 10 mg/mL 70069-0151-01 | Somerset | 1 vial | — | AP | FDA listed | — |
| Cisatracurium besylate 10 mg/mL 70436-0114-82 | Slate | 10 vials | — | AP | FDA listed | — |
| cisatracurium besylate 10 mg/mL 70710-1534-06 | Zydus | 10 vials | — | AP | FDA listed | — |
| Cisatracurium Besylate 200 mg/20mL 71288-0713-21 | Meitheal | 10 vials | — | AP | FDA listed | — |
| Cisatracurium Besylate 200 mg/20mL 72485-0513-10 | Armas | 10 vials | — | AP | FDA listed | — |
| cisatracurium besylate 10 mg/mLthis 72785-0009-06 | Zydus | 10 vials | — | AP | FDA listed | — |
| Cisatracurium Besylate 10 mg/mL 83634-0655-20 | Avenacy, | 10 vials | — | AP | FDA listed | — |
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file
Availability & generic status
🏛️
2020
On the market since
Feb 2020
📍
2026
Currently FDA-listed
6 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Cisatracurium inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 685928Z18A
A synthetic organic acid used as a buffer and pH adjuster in medicines. It helps maintain the proper acidity level so the drug stays stable and works effectively in the formulation.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
2 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed —
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 8, 2026
- FDA openFDA NDC Directory · synced Oct 8, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
Manufacturer & labeler
LabelerZydus Lifesciences Limited
Application holderZYDUS PHARMACEUTICALS USA INC
FDA applicationANDA212171 (ANDA)
Labeler code72785
First marketedFeb 2020
Product typeHuman Prescription Drug
Portfolio720 products on file
More NDCs from Zydus Lifesciences Limited labeler code 72785
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
- FDA openFDA NDC Directory · synced Oct 8, 2026
- Drugs@FDA
Full prescribing information FDA SPL
The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 Package Label / Principal Display Panel ▾
Principal Display Panel – Container Label (10 mg/5 mL) NDC 72785-0008-1 Cisatracurium Besylate Injection, USP 10 mg/5 mL* (2 mg/mL) WARNING: Paralyzing Agent For Intravenous Injection Preservative free 5 mL Single-Dose Vial Rx only Zydus Pharmaceuticals Principal Display Panel – Container Label (200 mg/20 mL) NDC 72785-0009-1 Cisatracurium Besylate Injection, USP 200 mg/20 mL* (10 mg/mL) WARNING: Paralyzing Agent For ICU use only. For Intravenous Injection Preservative free 20 mL Single-Dose Vial Rx only Zydus Pharmaceuticals Principal Display Panel – Carton Label (10 mg/5 mL) NDC 72785-0008-6 Cisatracurium Besylate Injection, USP 10 mg/5 mL* (2 mg/mL) WARNING: Paralyzing Agent For Intravenous Injection Preservative free 10 x 5 mL Single-Dose Vials Rx only Zydus Pharmaceuticals Principal Display Panel – Carton Label (200 mg/20 mL) NDC 72785-0009-6 Cisatracurium Besylate Injection, USP 200 mg/20 mL* (10 mg/mL) WARNING: Paralyzing Agent For ICU use only.
For Intravenous Injection Preservative free 10 x 20 mL Single-Dose Vials Rx only Zydus Pharmaceuticals image10 image11 image12 image13
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Prefer the government’s original formatting? View this label on DailyMed ↗
About this NDC listing & data coverage
Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.
Questions about this listing
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Zydus Lifesciences Limited. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Zydus Lifesciences Limited is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.